ArticleHealth economics review2026
Cost-effectiveness of zanubrutinib versus ibrutinib in the first-line treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China.
Ying Liu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.